Yes, the 6-in-1 vaccine is safe for infants.
The DTaP-IPV-Hib-HepB hexavalent vaccine (Vaxelis) is FDA-licensed and CDC-recommended for routine use in infants, with an established safety profile supported by extensive clinical trials and post-marketing surveillance. The vaccine was licensed in December 2018 and is indicated for primary vaccination at ages 2,4, and 6 months in children aged 6 weeks through 4 years 1.
Safety Evidence
The safety profile is well-characterized across multiple populations:
Clinical trial data: Over 6,800 children studied showed adverse event rates comparable to separately administered component vaccines 2. The most common reactions were fever (7.74/100,000 doses), crying (2.62/100,000), and injection site reactions like erythema (1.87/100,000) and swelling (1.28/100,000) 3.
Serious adverse events: Frequency of serious adverse events after DTaP-IPV-Hib-HepB was similar to that observed with separately administered DTaP, IPV, and Hib component vaccines 4. No vaccine-related serious adverse events were reported in major trials 5.
Post-marketing surveillance: 17 years of passive surveillance data for similar hexavalent vaccines (Infanrix hexa) confirms confidence in the safety profile with a favorable benefit-risk profile 3. An observed-to-expected analysis showed no increased risk of sudden death after vaccination 3.
Special Populations
Premature infants: The vaccine has an acceptable safety profile in premature infants, with adverse event incidence comparable to full-term infants (97.3% vs 96.3% for all AEs) 2. Premature infants should be vaccinated at the same chronological age as full-term infants 1.
HIV-exposed infants: The vaccine is immunogenic and safe in both HIV-exposed infected and uninfected infants, with results comparable to healthy infants 6.
Important Caveats
Not for birth dose: DTaP-IPV-Hib-HepB is not licensed for the birth dose of hepatitis B vaccine. Infants should receive monovalent HepB at birth, then can receive the hexavalent vaccine starting at 6 weeks 1.
Third dose timing: The minimum age for the third dose is 24 weeks to ensure adequate hepatitis B immune response. If given earlier, an additional HepB dose is needed at ≥24 weeks 1.
American Indian/Alaska Native infants: DTaP-IPV-Hib-HepB does not have preferential recommendation for AI/AN infants at this time, as data on antibody response after the first dose are not available. PRP-OMP-containing Hib vaccines are preferred for this population to provide earlier protection 1.
Concomitant administration: When co-administered with 13-valent pneumococcal conjugate vaccine, small increases in reporting of convulsions and hypotonic-hyporesponsive episodes have been observed, though clinical significance remains unknown 3.
Practical Considerations
The vaccine reduces the number of injections from 3-4 to 1 per visit, which improves vaccination coverage and compliance 1. It is supplied as a ready-to-use liquid formulation, minimizing preparation errors 7, 8. The vaccine can be administered concomitantly with other routine pediatric vaccines including rotavirus, pneumococcal conjugate, MMR, and varicella vaccines 1, 9.
Bottom line: The 6-in-1 vaccine meets rigorous FDA safety standards and is recommended by CDC/ACIP for routine infant immunization, with safety data from millions of doses distributed worldwide supporting its continued use 1, 3, 7.